MAP2K7 and melanoma: Trametinib is a highly selective allosteric mitogen-activated protein kinase kinase (MEK) inhibitor [37], that was originally approved for the treatment of malignant melanoma driven by the BRAF V600E mutation in combination with BRAF inhibitors, such as dabrafenib [38].